MYD88 and diffuse large B-cell lymphoma: In activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL), IRAK1 overexpression contributes to DLBCL aggressiveness in patients with MyD88 gain-of-function mutation [230].